ArticleJPRAS open2026
Long-term outcomes after single-stage augmentation mastopexy: A ten-year series and risk stratification model.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The existing literature on single-stage augmentation mastopexy is largely limited to short follow-up (<1 year), single surgeon series or outcomes in highly specific subgroups. The study aims to report long-term contemporary outcomes for single-stage augmentation mastopexy and to propose a risk stratification tool. Methods: Ten-year outcomes of consecutive cases of single-stage augmentation mastopexy between 2014-2024 were reported from a single center. Multivariate logistic regression identified risk factors for complication and re-operation and a risk-stratification tool was proposed. Results: 289 cases of single-stage augmentation mastopexy (Wise, 40.5% [117/289]; vertical with lateral extension, 26.3% [76/289]; vertical, 24.6% [71/289]) were performed including 45 patients (15.6%) with a history of previous augmentation or mastopexy. At a median follow-up of 46 months, implant- and tissue-related related complications occurred in 6.6% (19/289) and 26.0% (75/289) of cases, respectively. Re-operation occurred in 19.4% (56/289), of which 21.6% (12/56) were performed under local anaesthetic. Re-operation rates under general anaesthetic were 10.6%, 14.6% and 18.4% at 1, 3 and 5 years, respectively. The most common re-operation was revision mastopexy (11/289, 3.8%), followed by nipple areolar complex revision (9/289, 3.1%). Previous augmentation or mastopexy (OR 3.58; 95% CI,1.27-10.07), high-projection implants (OR 1.84; 95% CI,1.02-3.32) and smoking (OR 2.46; 95% CI,1.13-5.33) were associated with complication and/or re-operation. Landmark analysis identified implant-related complications in 4.8% (5/104) beyond 3 years and 2.0% (1/50) after 5 years, while tissue-related complications occurred in 1.0% (1/104) after 3 years and were absent beyond 5 years. Conclusions: Single-stage augmentation mastopexy can be performed safely in well-selected patients with promising long-term complication and re-operation rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.